ArticleInternational journal of ophthalmology2026
Safety and effectiveness of Bian-stone and moxibustion in treatment of meibomian gland dysfunction.
Article in International journal of ophthalmology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimTo propose a novel Bian-stone and moxibustion (BSM) therapy for meibomian gland dysfunction (MGD) treatment, and to evaluate its clinical efficacy and safety based on objective ocular surface parameters.
methodsA total of 140 patients with MGD were enrolled in this randomized controlled study and equally allocated (1:1 ratio) into the BSM group and the intense pulsed light (IPL) group. Patients in the BSM group received 30-minute BSM treatment every other day. Subjects in the IPL group completed four independent treatment sessions. The evaluated outcomes included the Ocular Surface Disease Index (OSDI), eyelid margin morphology, meibomian gland (MG) morphology and function, tear film breakup time (TBUT), ocular surface staining (OSS) score, Schirmer's test (ST), and tear meniscus height (TMH). All assessments were performed at baseline, as well as at 1- and 3-month follow-ups after treatment.
resultsThe BSM group consisted of 24 males and 47 females with a mean age of 59.04±16.50y, while the IPL group included 27 males and 42 females with a mean age of 60.39±15.90y. No significant differences in age, sex distribution, and clinical history were observed between the two groups. At 1 and 3mo post-treatment, the BSM group exhibited significant improvements in OSDI scores, eyelid margin hyperemia and neovascularization, MG expression, secretion status and gland loss, conjunctival hyperemia, and TBUT. Notably, the BSM group achieved superior improvements in OSDI scores and eyelid neovascularization compared with the IPL group at the 3-month follow-up. Additionally, significant reductions in eyelid margin edema and irregularity were only observed in the BSM group at 3mo after intervention.
conclusionBSM therapy can effectively relieve clinical symptoms and restore tear film homeostasis in patients with MGD, serving as a promising and viable therapeutic approach for MGD management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.